Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TACR3 | P29371 | 8/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667125 | 0.91 | LMNA (0.62) | LMNATACR3L3MBTL1TP53 | |
| SCHEMBL4667071 | 0.84 | LMNA (0.71) | LMNATACR3L3MBTL1TP53 | |
| SCHEMBL4961957 | 0.82 | TACR3 (0.51) | LMNATACR3L3MBTL1CYP2C9 | |
| SCHEMBL5049044 | 0.82 | LMNA (0.55) | LMNATACR3L3MBTL1CYP2C9TP53 | |
| SCHEMBL4667483 | 0.82 | LMNA (0.55) | LMNATACR3L3MBTL1CYP2C9TP53 | |
| SCHEMBL4962172 | 0.80 | TACR3 (0.50) | LMNATACR3L3MBTL1 | |
| SCHEMBL4667053 | 0.79 | TACR3 (0.55) | LMNATACR3OPRM1 | |
| SCHEMBL4667525 | 0.78 | LMNA (0.50) | LMNATACR3L3MBTL1CYP2C9TP53 | |
| SCHEMBL4667111 | 0.78 | LMNA (0.49) | LMNATACR3L3MBTL1CYP2C9TP53 | |
| SCHEMBL4964876 | 0.77 | TACR3 (0.51) | LMNATACR3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | claimed |
| EP-1940795-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007035156-A1 | N-OXO-HETEROCYCLE AND N-OXO-ALKYL QUINOLINE-4-CARBOXAMIDES AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |